Drugs / LY3076226
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02529553 | Sep 2015 → Mar 2018 | cancer of unknown primary site, metastatic malignant neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3076226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02529553 ↗ |
| Known as | Anti-fgfr3 adc ly3076226 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4298017 ↗ |
| Modality | Monoclonal antibody | “an antibody-drug conjugate composed of human IgG1 monoclonal antibody against the human FGFR3” PMID 34264412 ↗ Jul 2021 |
| Route | Intravenous | “as an intravenous infusion on Day 1 of each 21-day cycle” PMID 34264412 ↗ Jul 2021 |
| Target | FGFR3 | “human FGFR3” PMID 34264412 ↗ Jul 2021 |